Patients who had a delayed diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) had higher healthcare utilization, which resulted in higher pharmacy spending and both inpatient and outpatient spending, according to a poster presented at the April 2026 AMCP annual meeting in Nashville.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of heart failure. It is a rare disease that leads to a buildup of the transthyretin (TTR) in the left ventricle, the heart’s main pumping chamber. Transthyretin is a protein that helps transport thyroxine, which regulates the metabolism and retinol in the body, but when it accumulates in the left ventricle, it thickens and stiffens the heart muscle. That thickening causes shortness of breath and heart failure. Other symptoms include swelling in the lower legs, chest congestion, increased heart rate and heart palpitations.